c-ski对大鼠皮肤成纤维细胞增殖的调节作用及机制

c-ski是成纤维细胞增殖的复杂调节子,它对中胚层来源的皮肤成纤维细胞增殖的作用还不清楚。在观察正常成纤维细胞周期c-ski表达的时相特点的基础上,通过体外转染c-ski,观察它对细胞增殖活性、细胞周期进展以及周期蛋白表达的影响。结果显示：c-ski mRNA表达在加入血清后开始升高,在细胞周期G,期的高峰期达到峰值,S期显著下降,在G2／M期维持在较低的水平：转染的c-ski可以以剂量依赖的方式增加细胞的增殖活性,并且可以逆转Smad3对细胞增殖活性的抑制作用;C-ski使成纤维细胞提前达到G0／G1期的最低点,进入S期：同时细胞G1期周期蛋白cyclinD的表达增加。这些结果表明：C-ski是皮肤成纤维细胞G1期的调节子,通过加快G1期进展促进增殖,抑制Smad3活性,促进cyclinD的表达可能与这一作用的分子机制有关。     

CEACAM1异常表达对白血病BALL-1细胞增殖的影响

通过si RNA技术抑制癌胚抗原相关粘附分子CEACAM1在人急性B淋巴细胞白血病细胞系BALL-1中的表达,体外实验研究异常表达于白血病B细胞的CEACAM1对细胞增殖的影响。应用CCK-8法测定细胞增殖发现CEACAM1表达下调后BALL-1细胞的增殖能力明显下降。细胞周期分析结果显示CEACAM1被抑制后细胞增殖状态表现为S期细胞百分比降低,G0/G1期细胞比例升高,提示CEACAM1表达下调是通过引起细胞周期停滞在G0/G1期来降低细胞增殖的,表明CEACAM1本身对白血病B细胞具有促进增殖的作用。     

人源核小体组装蛋白1类似蛋白5（NAP1L5）促进293T细胞增殖

人源NAP1L5为核小体组装蛋白（NAP-1）家族成员,目前功能未知。肝癌研究暗示Nap1l5可能为抑癌基因,抑制细胞增殖;但NAP-1家族其他功能已知的一些成员,可促进细胞增殖和加快周期进程。人源NAP1L5是促进还是抑制细胞增殖,目前未知。本研究里,我们发现过表达Nap1l5促进293T细胞增殖,抑制表达则降低293T细胞增殖速度。细胞周期分析表明：Nap1l5过表达增加G2期、减少G1期细胞比例;抑制Nap1l5表达,则增加G1期、减少G2期细胞比例。我们的研究表明：人源NAP1L5会加快293T细胞周期进程,促进增殖,并且提示原来关于Nap1l5是抑癌基因的推测是不对的。     

孕激素诱导cyclin G1在小鼠子宫内膜上皮细胞的表达及其对细胞增殖的影响

本文在体外培养条件下研究卵巢激素诱导小鼠子宫内膜上皮细胞cyclin G1的表达及细胞增殖和细胞周期进程的变化,以探讨孕激素依赖的细胞周期调控因子cyclin G1对子宫内膜上皮细胞增殖的负调控作用.原代培养小鼠子宫内膜上皮细胞,待其生长汇合后分为4组:对照组(C组)、雌激素组(E组)、孕激素组(P组)、雌、孕激素共同作用组(EP组).加入相应激素作用24 h后,用细胞免疫化学方法检测各组细胞cyclin G1的表达水平:四甲基偶氮唑蓝(MTT)比色法检测各组细胞活力,间接观察子宫内膜上皮细胞的增殖情况;用流式细胞仪检测分布在细胞周期各时相的子宫内膜上皮细胞所占百分数.细胞免疫化学结果显示,cyclin G1在C组和E组子宫内膜上皮细胞上无明显表达,而在P组和EP组子宫内膜上皮细胞中表达明显,且定位于细胞核内.MTT法结果显示,与C组相比,E组细胞活力明显增高,而P组和EP组的细胞活力均明显下降,表明雌激素能促进子宫内膜上皮细胞增殖,而孕激素则具有抑制子宫内膜上皮细胞增殖的作用.流式细胞术检测显示,与C组相比,E组中处于S期的子宫内膜上皮细胞百分数增多;P组与EP组中处于S期的子宫内膜上皮细胞百分数明显减少,而处于G1期的细胞百分数和G2/M期的细胞百分数则明显增加.上述结果提示,孕激素依赖的cyclin G1可能通过阻滞细胞周期进程来参与孕激素对子宫内膜上皮细胞增殖的负调控作用.     

Kv1．3钾离子通道在卵巢癌细胞株中的表达及活性

目的：研究Kv1.3钾离子通道在SKOV3卵巢癌细胞中的表达及其在细胞增殖和细胞周期中的作用。方法：应用RT—PCR和免疫细胞化学鉴别Kv1.3钾离子通道在SKOV3卵巢癌细胞中的表达。应用MTT和流式细胞技术观察KV1.3钾离子通道对SKOV3卵巢癌细胞增殖及细胞周期的影响。结果：4-氨基吡啶是Kv1.3钾离子通道特异性阻滞剂。不同浓度的4－氨基吡啶可以明显抑制SKOV3细胞的增殖,并且细胞周期也受到影响。G0／G1细胞比例增加,S期和G2/M期细胞比例下降。结论：Kv1.3钾离子通道在SKOV3卵巢癌细胞中表达,并且在细胞增殖及细胞周期变换中扮演着重要的角色。     

Kv1.3 钾离子通道在卵巢癌细胞株中的表达及活性

目的:研究Kv1.3钾离子通道在SKOV3卵巢癌细胞中的表达及其在细胞增殖和细胞周期中的作用。方法:应用RT-PCR和免疫细胞化学鉴别Kv1.3钾离子通道在SKOV3卵巢癌细胞中的表达。应用MTT和流式细胞技术观察KV1.3钾离子通道对SKOV3卵巢癌细胞增殖及细胞周期的影响。结果:4-氨基吡啶是Kv1.3钾离子通道特异性阻滞剂。不同浓度的4-氨基吡啶可以明显抑制SKOV3细胞的增殖,并且细胞周期也受到影响。G0/G1细胞比例增加,S期和G2/M期细胞比例下降。结论:Kv1.3钾离子通道在SKOV3卵巢癌细胞中表达,并且在细胞增殖及细胞周期变换中扮演着重要的角色。     

维生素C诱导人宫颈癌Caski细胞凋亡及其分子机制的研究

为了研究维生素C对人宫颈癌Caski细胞体外抑制、诱导凋亡的作用及其分子机制,使用不同剂量维生素C处理人宫颈癌Caski细胞,采用噻唑蓝(MTT)法检测药物对细胞增殖的抑制作用;流式细胞仪检测Cas-ki细胞周期变化;琼脂糖电泳法观察凋亡细胞DNA Ladder现象;Western blot检测凋亡相关蛋白Bcl-2、Bax和E6的表达以及Caspase 3的激活;荧光染色观察细胞线粒体膜电位的改变.分析发现,维生素C可显著抑制人宫颈癌Caski细胞增殖,呈现明显的时间和剂量依赖性;将细胞阻滞于S期;诱导细胞凋亡,下调Bcl-2和E6、上调Bax蛋白表达,促进Caspase3活化,降低线粒体膜电位.表明维生素C在体外可有效抑制人宫颈癌Caski细胞增殖,诱导细胞凋亡.     

T型钙通道α1G亚单位在细胞增殖中的功能研究

利用稳定过表达人类T型钙通道α_(1G)亚单位的HEK-293细胞研究了T型钙通道在细胞增殖中的作用。RT-PCR和标准全细胞膜片钳记录分别从mRNA转录水平和T型钙通道蛋白功能水平验证了α_(1G)单位的过表达的实现。生长曲线表明,T型钙通道α_(1G)亚单位的过表达能显著促进细胞增殖,HEKα_(1G)~+细胞的细胞群体倍增时间(13.7±0.3h)比对照HEK-293细胞的细胞群体倍增时间(22.1±1.1h)缩短了约8h;流式细胞分析结果也与此吻合,在稳定过表达了人类T型钙通道α_(1G)亚单位的细胞处于S期的细胞百分率比对照HEK-293细胞高,相反地处于G_0/G_1期的百分率比对照HEK-293细胞低,以上结果证明过表达T型钙通道α_(1G)亚单位能促进细胞增殖;T型钙通道特异性阻断剂mibefradil抑制HEKα_(1G)~+细胞增殖,IC_(50)为3.5/μmol/L,表明在HEK-293细胞过表达T型钙通道对细胞增殖的促进作用可以被T型钙通道特异性阻断剂mibefradil抑制,这就进一步证明了T型钙通道在促进细胞增殖方面的直接作用。Western杂交结果提示了T型钙通道α_(1G)亚单位的表达是通过某种信号途径提高了与细胞周期有关的蛋白质,cyclin A、cyclin E和CDK2的表达水平,从而刺激了细胞周期的进程。本研究有助于理解细胞增殖的机制并为开发治疗与细胞增殖异常有关疾病的新药提供了理论依据。     

人椎间盘髓核来源的诱导多能干细胞重编程及功能的研究

椎间盘退变始发于髓核组织,获得足够有功能的髓核细胞是研究及治疗椎间盘退变的关键.而人诱导多能干细胞(induced pluripotent stem cell,iPSC)不仅为建立疾病模型以研究疾病发生发展机制开辟了道路,还在再生医学领域展现出了广阔的应用前景.我们首先从椎间盘退变患者微创手术获得的髓核组织内分离髓核细胞,将携带OCT3/4、SOX2、KLF4和c-MYC的仙台病毒(Sendai virus,Se V)转染髓核细胞,重编程获得iPSC.通过检测多能细胞特异性标志、体内成瘤实验、甲基化及核型分析对所获得的iPSC进行鉴定.并以皮肤成纤维细胞来源iPSC作为对照,在二维和三维水凝胶中对iPSC进行定向分化,检测髓核细胞相关蛋白和基因的表达,比较分析2种iPSC向髓核细胞的分化效率.结果显示,iPSC能表达多能细胞特异性标志,具有正常的二倍体核型,畸胎瘤实验显示三个胚层的出现.诱导分化后的iPSC表达髓核相关基因和蛋白,在水凝胶中诱导培养后,iPSC表达更多的髓核相关基因和蛋白.髓核来源的iPSC与成纤维细胞来源的iPSC相比,可表达更多的髓核相关基因和蛋白.本研究首次将患者退变髓核细胞重编程成iPSC,并在水凝胶内将其诱导分化为髓核样细胞,为椎间盘退变个体化细胞治疗奠定基础.     

MS4A12基因在结肠癌中的表达及对结肠癌细胞增殖的影响

探讨MS4A12基因在结肠癌发生过程中的表达及其与结肠癌细胞增殖的关系,利用GEO数据库下载含正常结肠、不典型增生结肠腺瘤和结肠癌组织的基因芯片数据GSE37364,对MS4A12基因表达进行标准化后,再对其进行表达差异分析。通过对结肠癌细胞系Lo Vo进行MS4A12基因沉默,以此研究MS4A12基因对结肠癌细胞增殖的影响。MTT法检测细胞增殖,流式细胞术检测细胞周期,荧光定量PCR检测相关基因的表达。MS4A12基因在正常、腺瘤和结肠癌组织中表达依次降低(p0.001)。MS4A12基因沉默后,细胞增殖较对照明显升高(p0.05),且S期细胞比例较对照组升高,G1期细胞比例降低(p0.05)。本研究发现抑制MS4A12基因可以明显促进结肠癌细胞增殖,且在结肠癌发生过程中其表达逐渐降低,这提示MS4A12可能与结肠癌的发生有关并可为结肠癌早期诊断提供依据。     

Generation of induced pluripotent stem cells from human nasal epithelial cells using a sendai virus vector

The generation of induced pluripotent stem cells (iPSCs) by introducing reprogramming factors into somatic cells is a promising method for stem cell therapy in regenerative medicine. Therefore, it is desirable to develop a minimally invasive simple method to create iPSCs. In this study, we generated human nasal epithelial cells (HNECs)-derived iPSCs by gene transduction with Sendai virus (SeV) vectors. HNECs can be obtained from subjects in a noninvasive manner, without anesthesia or biopsy. In addition, SeV carries no risk of altering the host genome, which provides an additional level of safety during generation of human iPSCs. The multiplicity of SeV infection ranged from 3 to 4, and the reprogramming efficiency of HNECs was 0.08-0.10%. iPSCs derived from HNECs had global gene expression profiles and epigenetic states consistent with those of human embryonic stem cells. The ease with which HNECs can be obtained, together with their robust reprogramming characteristics, will provide opportunities to investigate disease pathogenesis and molecular mechanisms in vitro, using cells with particular genotypes.     

Generation of induced pluripotent stem cells from CD34+ cells across blood drawn from multiple donors with non-integrating episomal vectors

The methodology to create induced pluripotent stem cells (iPSCs) affords the opportunity to generate cells specific to the individual providing the host tissue. However, existing methods of reprogramming as well as the types of source tissue have significant limitations that preclude the ability to generate iPSCs in a scalable manner from a readily available tissue source. We present the first study whereby iPSCs are derived in parallel from multiple donors using episomal, non-integrating, oriP/EBNA1-based plasmids from freshly drawn blood. Specifically, successful reprogramming was demonstrated from a single vial of blood or less using cells expressing the early lineage marker CD34 as well as from unpurified peripheral blood mononuclear cells. From these experiments, we also show that proliferation and cell identity play a role in the number of iPSCs per input cell number. Resulting iPSCs were further characterized and deemed free of transfected DNA, integrated transgene DNA, and lack detectable gene rearrangements such as those within the immunoglobulin heavy chain and T cell receptor loci of more differentiated cell types. Furthermore, additional improvements were made to incorporate completely defined media and matrices in an effort to facilitate a scalable transition for the production of clinic-grade iPSCs.     

MicroRNA-195 Inhibits the Proliferation of Human Glioma Cells by Directly Targeting Cyclin D1 and Cyclin E1

Glioma proliferation is a multistep process during which a sequence of genetic and epigenetic alterations randomly occur to affect the genes controlling cell proliferation, cell death and genetic stability. microRNAs are emerging as important epigenetic modulators of multiple target genes, leading to abnormal cellular signaling involving cellular proliferation in cancers.In the present study, we found that expression of miR-195 was markedly downregulated in glioma cell lines and human primary glioma tissues, compared to normal human astrocytes and matched non-tumor associated tissues. Upregulation of miR-195 dramatically reduced the proliferation of glioma cells. Flow cytometry analysis showed that ectopic expression of miR-195 significantly decreased the percentage of S phase cells and increased the percentage of G1/G0 phase cells. Overexpression of miR-195 dramatically reduced the anchorage-independent growth ability of glioma cells. Furthermore, overexpression of miR-195 downregulated the levels of phosphorylated retinoblastoma (pRb) and proliferating cell nuclear antigen (PCNA) in glioma cells. Conversely, inhibition of miR-195 promoted cell proliferation, increased the percentage of S phase cells, reduced the percentage of G1/G0 phase cells, enhanced anchorage-independent growth ability, upregulated the phosphorylation of pRb and PCNA in glioma cells. Moreover, we show that miR-195 inhibited glioma cell proliferation by downregulating expression of cyclin D1 and cyclin E1, via directly targeting the 3′-untranslated regions (3′-UTR) of cyclin D1 and cyclin E1 mRNA. Taken together, our results suggest that miR-195 plays an important role to inhibit the proliferation of glioma cells, and present a novel mechanism for direct miRNA-mediated suppression of cyclin D1 and cyclin E1 in glioma.     

Molecular insights into the heterogeneity of telomere reprogramming in induced pluripotent stem cells

Rejuvenation of telomeres with various lengths has been found in induced pluripotent stem cells (iPSCs). Mechanisms of telomere length regulation during induction and proliferation of iPSCs remain elusive. We show that telomere dynamics are variable in mouse iPSCs during reprogramming and passage, and suggest that these differences likely result from multiple potential factors, including the telomerase machinery, telomerase-independent mechanisms and clonal influences including reexpression of exogenous reprogramming factors. Using a genetic model of telomerase-deficient (Terc(-/-) and Terc(+/-)) cells for derivation and passages of iPSCs, we found that telomerase plays a critical role in reprogramming and self-renewal of iPSCs. Further, telomerase maintenance of telomeres is necessary for induction of true pluripotency while the alternative pathway of elongation and maintenance by recombination is also required, but not sufficient. Together, several aspects of telomere biology may account for the variable telomere dynamics in iPSCs. Notably, the mechanisms employed to maintain telomeres during iPSC reprogramming are very similar to those of embryonic stem cells. These findings may also relate to the cloning field where these mechanisms could be responsible for telomere heterogeneity after nuclear reprogramming by somatic cell nuclear transfer.     

Inducing pluripotency in vitro: recent advances and highlights in induced pluripotent stem cells generation and pluripotency reprogramming

Induced pluripotent stem cells (iPSCs) are considered patient‐specific counterparts of embryonic stem cells as they originate from somatic cells after forced expression of pluripotency reprogramming factors Oct4, Sox2, Klf4 and c‐Myc. iPSCs offer unprecedented opportunity for personalized cell therapies in regenerative medicine. In recent years, iPSC technology has undergone substantial improvement to overcome slow and inefficient reprogramming protocols, and to ensure clinical‐grade iPSCs and their functional derivatives. Recent developments in iPSC technology include better reprogramming methods employing novel delivery systems such as non‐integrating viral and non‐viral vectors, and characterization of alternative reprogramming factors. Concurrently, small chemical molecules (inhibitors of specific signalling or epigenetic regulators) have become crucial to iPSC reprogramming; they have the ability to replace putative reprogramming factors and boost reprogramming processes. Moreover, common dietary supplements, such as vitamin C and antioxidants, when introduced into reprogramming media, have been found to improve genomic and epigenomic profiles of iPSCs. In this article, we review the most recent advances in the iPSC field and potent application of iPSCs, in terms of cell therapy and tissue engineering.     

SOX2 and SOX2-MYC Reprogramming Process of Fibroblasts to the Neural Stem Cells Compromised by Senescence

Tumorigenic potential of induced pluripotent stem cells (iPSCs) infiltrating population of induced neural stem cells (iNSCs) generated from iPSCs may limit their medical applications. To overcome such a difficulty, direct reprogramming of adult somatic cells into iNSCs was proposed. The aim of this study was the systematic comparison of induced neural cells (iNc) obtained with different methods—direct reprogramming of human adult fibroblasts with either SOX2 (SiNSc-like) or SOX2 and c-MYC (SMiNSc-like) and induced pluripotent stem cells differentiation to ebiNSc—in terms of gene expression profile, differentiation potential as well as proliferation properties. Immunocytochemistry and real-time PCR analyses were used to evaluate gene expression profile and differentiation potential of various iNc types. Bromodeoxyuridine (BrdU) incorporation and senescence-associated beta-galactosidase (SA-β-gal) assays were used to estimate proliferation potential. All three types of iNc were capable of neuronal differentiation; however, astrocytic differentiation was possible only in case of ebiNSc. Contrary to ebiNSc generation, the direct reprogramming was rarely a propitious process, despite 100% transduction efficiency. The potency of direct iNSCs-like cells generation was lower as compared to iNSCs obtained by iPSCs differentiation, and only slightly improved when c-MYC was added. Directly reprogrammed iNSCs-like cells were lacking the ability to differentiate into astrocytic cells and characterized by poor efficiency of neuronal cells formation. Such features indicated that these cells could not be fully reprogrammed, as confirmed mainly with senescence detection. Importantly, SiNSc-like and SMiNSc-like cells were unable to achieve the long-term survival and became senescent, which limits their possible therapeutic applicability. Our results suggest that iNSCs-like cells, generated in the direct reprogramming attempts, were either not fully reprogrammed or reprogrammed only into neuronal progenitors, mainly because of the inaccuracies of currently available protocols.